{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-091945","form_type":"8-K","ticker":null,"cik":"0001785173","company_name":"89bio, Inc.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.096744+00:00","generated_at":"2026-06-04T00:29:19.623589+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"89bio enters $135M agreement with BiBo to build pegozafermin production facility","bullets":["Collaboration agreement with BiBo to construct a production facility for pegozafermin commercial supply.","89bio to pay $135M total; 45% due in Q3 2024, remainder on milestone achievements.","Facility located in Lin-gang Special Area, Shanghai Pilot Free Trade Zone.","Work order for commercial supply under existing MSA expected before facility operations.","Negotiated discount on commercial supply until payment recouped."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-091945","json":"https://secwatch.observer/filing/0001193125-24-091945.json","markdown":"https://secwatch.observer/filing/0001193125-24-091945.md","text":"https://secwatch.observer/filing/0001193125-24-091945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/0001193125-24-091945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/d818064d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:29:19.623589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16cfff62e8ec6d8ba812c2453666cb0a5ded3e1d","claim":"89bio, Inc. entered into Collaboration Agreement with BiBo Biopharma Engineering Co., Ltd. valued at $135 million (effective 2024-04-04).","evidence_excerpt":"On April 4, 2024, 89bio, Inc., a Delaware corporation (the “Company”), entered into a collaboration agreement (the “Collaboration Agreement”) with BiBo Biopharma Engineering Co., Ltd., a company incorporated under the laws of the People’s Republic of China (“BiBo”), pursuant to which BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved (the “Production Facility”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/0001193125-24-091945-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"BiBo Biopharma Engineering Co., Ltd."},{"label":"Value","value":"$135 million"},{"label":"Effective","value":"2024-04-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}